Tests elecoglipron against placebo in adults with chronic kidney disease
Tests elecoglipron versus placebo in adults with chronic kidney disease, alongside standard care.
Plain-language title generated from the registry record
Registry title: A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
Key facts
- Where
- Bedzin, Bialystok, Czeladz, Katowice, Kwidzyn, Lodz, Lublin, Olsztyn, Poznan, Rzeszów, Swiecie, Tczew, Warsaw, Włocławek, and Zywiec, PolandSee the 18 sites
- Phase
- Phase 3
Where in Poland
- Syberka-Clinhouse Sp. z o.o.Bedzin, PolandTaking people
- Kresmed Sp. z o. o.Bialystok, PolandTaking people
- Centrum-Med Anna Drzewiecka Elzbieta Drzewiecka Sp. j.Czeladz, PolandTaking people
- Pro Familia Altera Sp. z o.o.Katowice, PolandTaking people
- Centrum Badan Klinicznych Pi-House Sp. z o.o.Kwidzyn, PolandTaking people
- Samodzielny Publiczny Zaklad Opieki Zdrowotnej Centralny Szpital Kliniczny Uniwersytetu Medycznego W LodziLodz, PolandTaking people
- Clinical Best Solutions Sp. z o.o. S.K.Lublin, PolandTaking people
- Etyka Osrodek Badan Klinicznych Tomasz Pesta S.K.A.Olsztyn, PolandTaking people
- Wojewódzki Szpital Specjalistyczny w OlsztynieOlsztyn, PolandTaking people
- Maciej Wiza Gaja Poradnie LekarskiePoznan, PolandTaking people
- Uniwersytecki Szpital Kliniczny w PoznaniuPoznan, PolandTaking people
- EMED Centrum Uslug Medycznych Ewa SmialekRzeszów, PolandTaking people
- Nowy Szpital Sp. z o.o.Swiecie, PolandTaking people
- Szpitale Tczewskie S.A.Tczew, PolandTaking people
- Care Access Polska Sp. Z o.o.Warsaw, PolandTaking people
- Wojskowy Instytut Medyczny Panstwowy Instytut BadawczyWarsaw, PolandTaking people
- Kardio Life - Tomasz BorkowskiWłocławek, PolandTaking people
- Icz Healthcare Sp. z o.o.Zywiec, PolandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AstraZeneca
- Trial code
- NCT07753993EU 2025-523994-41-00
- Record updated
- 9 September 2026
- Original description
This is a Phase III, randomized, double-blind, parallel-group, placebo-controlled multicenter study to investigate outcomes with elecoglipron compared with placebo in participants with CKD with and without T2DM who are on background SGLT2i (dapagliflozin) as GDMT and other SoC treatments for CKD.Read full original descriptionShow less
A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled Multicenter Study to Evaluate the Effect of Elecoglipron in Reducing Renal Outcomes and Mortality in Participants With Chronic Kidney Disease (Elevate-CKD)
This is a Phase III, randomized, double-blind, parallel-group, placebo-controlled multicenter study to investigate outcomes with elecoglipron compared with placebo in participants with CKD with and without T2DM who are on background SGLT2i (dapagliflozin) as GDMT and other SoC treatments for CKD.
Inclusion: Adults with confirmed CKD; UACR ≥30 mg/g and eGFR ≥20 mL/min/1.73 m² within specified ranges; On stable, patient maximum tolerated, labeled daily dose of ACEI or ARB for ≥4 weeks at least 28 days before screening.
Exclusion: Currently receiving, or anticipated to receive, therapeutic intervention for diabetic retinopathy and/or macular edema; Have had more than one episode of severe hypoglycemia within 180 days prior to screening, or hypoglycemia unawareness; Acute coronary syndrome, major cardiac procedure, stroke, or TIA within 3 months prior to screening; History of type 1 diabetes mellitus; Clinically significant condition affecting the upper GI tract or chronic use of any medication that affects gastric motility or gastric emptying; History of acute or chronic pancreatitis; History/family history (first degree) of medullary thyroid cancer or MEN2; HbA1c ≥10% (86 mmol/mol) at screening; BMI <23 kg/m² at screening.